La Celle St. Cloud, France

Martin M Rottman

USPTO Granted Patents = 12 

Average Co-Inventor Count = 6.9

ph-index = 4

Forward Citations = 32(Granted Patents)


Location History:

  • Cambridge, MA (US) (2017 - 2020)
  • La Celle St Cloud, FR (2020)
  • La Celle-Saint-Cloud, FR (2017 - 2021)
  • St. Cloud, FR (2017 - 2023)

Company Filing History:


Years Active: 2017-2023

Loading Chart...
12 patents (USPTO):Explore Patents

Title: The Innovations of Martin M Rottman

Introduction

Martin M Rottman is a notable inventor based in La Celle St. Cloud, France. He has made significant contributions to the field of microbiology through his innovative patents. With a total of 12 patents to his name, Rottman has focused on developing engineered microbe-targeting molecules that have various applications in medical diagnostics and treatment.

Latest Patents

Rottman's latest patents include groundbreaking work on engineered microbe-targeting molecules and their uses. One of his notable inventions describes engineered microbe-targeting or microbe-binding molecules, which can be linked to substrates such as magnetic microbeads. These molecules are designed to bind and capture microbes, making them useful in diagnosing and treating infections, including sepsis. Another patent focuses on the capture and detection of gram-positive bacteria, further showcasing his commitment to advancing medical technology.

Career Highlights

Rottman is affiliated with Harvard College, where he continues to contribute to research and innovation in microbiology. His work has garnered attention for its potential to improve diagnostic methods and treatment options for microbial infections.

Collaborations

Rottman has collaborated with esteemed colleagues such as Michael Super and Mark J Cartwright, enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Martin M Rottman's contributions to the field of microbiology through his innovative patents highlight his role as a leading inventor. His work on engineered microbe-targeting molecules has the potential to revolutionize the diagnosis and treatment of infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…